Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NKG2C-KE
- Development stage
- Preclinical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
NKG2C-KE is a trispecific killer engager biologic constructed to direct and activate natural killer (NK) cells expressing the NKG2C receptor, providing targeted delivery of interleukin-15 (IL-15) and redirecting these adaptive NK cells to CD33-positive tumor cells[1]. Its mechanism includes engaging NKG2C^+^ NK cells, delivering IL-15 specifically to this subpopulation, and linking these adaptive NK cells to tumor-associated antigens (specifically CD33), thereby boosting cytotoxicity and persistence of NK cells against acute myeloid leukemia (AML) cells[1]. Developed as an advanced immunotherapy tool, NKG2C-KE expands and activates NKG2C^+^ adaptive NK cells, mimicking signals seen in cytomegalovirus (CMV) infection, and offers a precision therapeutic approach for targeting AML by promoting proliferation, degranulation, cytokine production, and cytotoxic activity against CD33^+^ blasts and cell lines[1].
- Brand names
- NKG2C-KENKG-2C-KENKG 2C-KE
- Other names
- NKG2C-KENKG-2C-KENKG 2C-KEanti-NKG2C/IL-15/anti-CD33 killer engager
02
Targets
IL15RA (Interleukin-15 receptor subunit alpha)KLRC2 (CD94/NKG2C receptor)CD33 (Myeloid cell surface antigen CD33)
Beyond the preview
Go deeper on NKG2C-KE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NKG2C-KE.